LucidQuest was asked to support a haematology brand team of a large pharmaceutical company in better understanding current and future treatment options in CML.
After brainstorming with the client, we focused our research on interviews with competitors and leading KOLs in the CML space, in order to uncover their current preferences and future thinking about the disease’s Tx evolution.
We were able to identify the key emerging trends in terms of lines of Tx (based on new competitors entering the space) and were able to provide a clear view of the existing and likely future states of CML Tx in both US and EU. Our client was able to use the findings in a strategic simulation workshop, which we also moderated.